QuidelOrtho Q3 2026 Earnings Conference Call - ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC

Financial Performance:

• Total reported revenue was $619 million, a 12% year-over-year decline on a constant currency basis; revenue excluding China, respiratory, and donor screening wind-down grew 3%.
• Labs revenue outside China grew 4%, while immunohematology outside China grew 3%.
• Point-of-care revenue declined 27% year-over-year, driven by a 39% drop in respiratory testing.
• China revenue fell 45% year-over-year due to destocking triggered by nationwide IVD pricing guidelines.
• Adjusted gross margin was 47.8%, down 90 basis points year-over-year; gross margin included approximately 300 basis points of non-recurring benefits from tariff refunds and vendor credits.
• Non-GAAP operating expenses were $210 million (34% of revenue), down 3% in absolute dollars; adjusted EBITDA was $148 million with a 24% margin; adjusted EPS was $0.31.
• Operating cash flow improved to $20 million (up $65 million year-over-year); free cash flow was approximately break-even, a significant improvement from negative $95 million in the prior year period.
• Net debt stood at $2.8 billion with net leverage of 4.5 times adjusted EBITDA; cash balance was $166 million.
• A credit agreement was amended to increase the maximum consolidated leverage ratio to 5.5 times adjusted EBITDA through Q2 2028.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance narrowed to $2.50–$2.55 billion from $2.52–$2.60 billion, primarily reflecting an updated view on China destocking and softer respiratory trends.
• Full-year 2026 adjusted EBITDA guidance remains $540–$545 million; adjusted EPS guidance is $0.65–$0.70.
• China revenue is projected to represent approximately 8% of total revenue in 2026 and 4–5% in 2027; provincial implementation of pricing guidelines is expected to begin in six provinces by year-end, with full impact expected in 2027.
• The respiratory season outlook remains cautious based on Q3 trends, though an early start to the season has been observed.
• A new cost transformation program aims to deliver over $80 million in annual savings starting in 2027.
• One-time restructuring charges of $30–$35 million are expected in Q4 2026, with the majority of cash outflows occurring in Q4 2026.

Business Segments and Product Lines:

• The company is restructuring its operating model into two distinct businesses: Core Diagnostics (Labs, Immunohematology, Informatics) and Point-of-Care Diagnostics (SOFIA, TRIAGE, NuLEXA).
• Core Diagnostics focuses on clinical laboratories, hospitals, and blood banks; Point-of-Care targets clinics, physician offices, and emergency rooms to improve customer focus and accountability.
• NuLEXA, the point-of-care molecular platform, is in early launch stages; the company is building manufacturing capabilities and expanding the installed base ahead of the 2027–2028 respiratory season.
• The Vitros 450 analyzer is being expanded to additional key international markets to support low-volume and community-based labs.
• The U.S. donor screening business is actively winding down.

Market and Competitive Landscape:

• China's IVD pricing guidelines have broadly removed pricing differentiation by methodology, creating significant pricing pressure and competitive intensity expected to intensify in 2027.
• Underlying fundamentals outside China remain resilient, with low-to-mid single-digit organic growth in labs and immunohematology supported by a large installed base and strong customer relationships.
• The respiratory market environment is softer than the prior year, driven by lower demand rather than testing protocol changes, with market share remaining stable.
• Geographic growth is broad-based outside China, with strength noted in Latin America, Japan, and Asia-Pacific.

Risks and Challenges:

• Uncertainty regarding the provincial implementation timeline for China's IVD pricing guidelines, with potential for extended destocking and pricing pressure into 2027.
• Volatility in respiratory testing demand, which is inherently variable and impacts point-of-care revenue significantly.
• Near-term financial headwinds from revenue declines in China and respiratory segments, leading to a slight increase in net leverage ratios.
• Execution risk associated with the transition to the new operating model and the potential for customer-facing disruption during restructuring.

Management Commentary and Tone:

• Management described the underlying business as "resilient" despite significant near-term headwinds, emphasizing a shift from a geographic model to a business-unit-led model.
• The tone was cautious but determined, framing the restructuring not as a temporary fix but as a structural improvement to enable sustainable, profitable growth.
• Management emphasized "disciplined execution" as the priority to improve profitability, cash flow, and reduce leverage.
• CEO Brian Blazer and CFO Micah Young highlighted that the $80 million savings target is incremental to previous cost-saving efforts and is designed to offset China headwinds while strengthening the earnings profile.

Analyst Questions and Answers:

• Operating Model Change: Analysts asked about the shift from geographic to business-unit management; management confirmed this increases accountability and aligns R&D investments with specific customer needs (clinics vs. labs).
• Savings Magnitude: Management clarified the $80 million savings are new and incremental, not part of prior guidance, with staffing reductions being the primary initial driver.
• Labs Deceleration: Management attributed the deceleration in Labs (excluding China) from 9% to 4% to timing of tenders and softness in the Middle East/EMEA, rather than a fundamental trend change.
• Cash Flow and Leverage: CFO noted progress on free cash flow (break-even in Q3 vs. negative in Q2) but cautioned that Q4 will be impacted by restructuring cash outflows; the credit line amendment provides flexibility for the transition.
• Asset Sales: Regarding rumors of selling the NuLEXA asset or the China franchise, management stated they are "looking at every option" to support deleveraging but currently view China economics as favorable long-term and have no immediate plans to divest.

Other Key Points:

• The company announced a dedicated cost transformation and enterprise restructuring program effective immediately.
• Net capital expenditures were reduced to $19 million in Q3, down from $49 million year-over-year, reflecting stricter capital allocation discipline.
• The company is proactively managing the transition to the new operating model to minimize disruption while preparing for the 2027 revenue mix shift driven by China's pricing changes.
• Management reiterated that protecting the long-term value of the China franchise and the installed base remains a priority despite current destocking pressures.